{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:02:15Z","timestamp":1792040535668,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02207-2","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T12:16:27Z","timestamp":1781093787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thromboembolic risk in subcutaneous versus intravenous immunoglobulin therapy: a systematic review and narrative meta-synthesis"],"prefix":"10.1007","volume":"26","author":[{"given":"Shihshuan","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"3S","key":"2207_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EE Perez","year":"2017","unstructured":"Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1\u201346.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2207_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance therapy in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35\u201346.","journal-title":"Lancet Neurol"},{"issue":"19","key":"2207_CR3","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367\u201375.","journal-title":"JAMA"},{"issue":"6","key":"2207_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","volume":"11","author":"E Nobile-Orazio","year":"2012","unstructured":"Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11(6):493\u2013502.","journal-title":"Lancet Neurol"},{"key":"2207_CR5","first-page":"CD001797","volume":"12","author":"F Eftimov","year":"2013","unstructured":"Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;12:CD001797.","journal-title":"Cochrane Database Syst Rev"},{"key":"2207_CR6","first-page":"CD002277","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12:CD002277.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2207_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"U Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIg) therapy. Autoimmun Rev. 2007;6(4):257\u20139.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"2207_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","volume":"155","author":"I Marie","year":"2006","unstructured":"Marie I, Maurey G, Herber R, et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714\u201321.","journal-title":"Br J Dermatol"},{"issue":"8794","key":"2207_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/0140-6736(92)90806-E","volume":"339","author":"WH Reinhart","year":"1992","unstructured":"Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet. 1992;339(8794):662\u20134.","journal-title":"Lancet"},{"key":"2207_CR10","unstructured":"US Food and Drug Administration. IGIV products: risk of thrombosis. FDA Drug Saf Communication. 2013."},{"issue":"11","key":"2207_CR11","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2021;28(11):3556\u201383.","journal-title":"Eur J Neurol"},{"issue":"8","key":"2207_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","volume":"10","author":"B van den Berg","year":"2014","unstructured":"van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469\u201382.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"2207_CR13","doi-asserted-by":"publisher","first-page":"e0159993","DOI":"10.1371\/journal.pone.0159993","volume":"11","author":"PR Bourque","year":"2016","unstructured":"Bourque PR, Pringle CE, Cameron W, et al. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis. PLoS ONE. 2016;11(8):e0159993.","journal-title":"PLoS ONE"},{"issue":"8","key":"2207_CR14","first-page":"674","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Blum S, Cornblath DR, et al. Subcutaneous immunoglobulin versus intravenous immunoglobulin in CIDP patients (ADVANCE-CIDP 1): a multicentre open-label randomised non-inferiority trial. Lancet Neurol. 2023;22(8):674\u201385.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2207_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","volume":"139","author":"M Berger","year":"2011","unstructured":"Berger M. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133\u201341.","journal-title":"Clin Immunol"},{"issue":"1","key":"2207_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.anai.2013.04.015","volume":"111","author":"RS Shapiro","year":"2013","unstructured":"Shapiro RS. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatric patients. Ann Allergy Asthma Immunol. 2013;111(1):51\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"2207_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","volume":"28","author":"M Berger","year":"2008","unstructured":"Berger M. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008;28(4):803\u201319.","journal-title":"Immunol Allergy Clin North Am"},{"key":"2207_CR18","first-page":"n71","volume":"372","author":"PRISMA Group","year":"2021","unstructured":"PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2207_CR19","unstructured":"Higgins JPT, Thomas J, Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Cochrane; 2023."},{"key":"2207_CR20","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2022."},{"issue":"7414","key":"2207_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"7109","key":"2207_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):651\u20135.","journal-title":"BMJ"},{"issue":"2","key":"2207_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1212\/WNL.44.2.223","volume":"44","author":"MC Dalakas","year":"1994","unstructured":"Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44(2):223\u20136.","journal-title":"Neurology"},{"issue":"11","key":"2207_CR24","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","volume":"60","author":"JB Caress","year":"2003","unstructured":"Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003;60(11):1822\u20134.","journal-title":"Neurology"},{"issue":"3","key":"2207_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","volume":"27","author":"ER Stiehm","year":"2013","unstructured":"Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171\u20138.","journal-title":"Transfus Med Rev"},{"issue":"3","key":"2207_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29(3):173\u201384.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"2207_CR27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ajh.24451","volume":"91","author":"EM Ammann","year":"2016","unstructured":"Ammann EM, Haskins CB, Fillman KM, et al. Intravenous immune globulin and thromboembolic adverse events: a systematic review and meta-analysis of RCTs. Am J Hematol. 2016;91(9):923\u201338.","journal-title":"Am J Hematol"},{"issue":"5","key":"2207_CR28","first-page":"555","volume":"120","author":"V Vacchiano","year":"2018","unstructured":"Vacchiano V, Liguori R, Pasini E, et al. Subcutaneous immunoglobulin treatment and thromboembolic risk. Ann Allergy Asthma Immunol. 2018;120(5):555\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"2207_CR29","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/jcm14041203","volume":"14","author":"M Dimou","year":"2025","unstructured":"Dimou M, Vacca A, S\u00e1nchez-Ram\u00f3n S, et al. Real-World Effectiveness, Safety, and Tolerability of Facilitated Subcutaneous Immunoglobulin 10% in Secondary Immunodeficiency Disease: A Systematic Literature Review. J Clin Med. 2025;14(4):1203.","journal-title":"J Clin Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02207-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02207-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02207-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:02:34Z","timestamp":1786975354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02207-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2207"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02207-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review of published data.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"297"}}